Art. -Nr.: HY-124600

NVR 3-778

Name: NVR 3-778
Brand: MedChemExpress
SKU: HY-124600
Price: 150.00 USD
Availability: InStock
Rating: 5 (3 reviews)

3 Cited Publications

Kundenbewertung

Based on 3 publication(s) in Google Scholar

NVR 3-778 is a first-in-Class and oral bioavailable HBV CAM (capsid assembly modulator) belonging to the SBA (sulfamoylbenzamide) class, with anti-HBV activity.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.88%
CAS. Nr.: 1445790-55-5
Formel: C₁₈H₁₆F₄N₂O₄S
Molecular Weight:432.39

Speicherung:

Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month

NVR 3-778 Chemical Structure

CAS. Nr.: 1445790-55-5

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (3)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

NVR 3-778 is a first-in-Class and oral bioavailable HBV CAM (capsid assembly modulator) belonging to the SBA (sulfamoylbenzamide) class, with anti-HBV activity^[1].

IC₅₀ & Target

HBV^[1]

Cellular Effect

Cell Line	Type	Value	Description	References
HepG2 2.2.15	CC₅₀	15.3 μM Compound: 1; NVR 3-778	Cytotoxicity against human HepG2.2.15 cells assessed as reduction in cell viability incubated for 3 days followed by replacement of fresh medium containing compound and measured after 3 days by cell titer glo-based luminescence assay Cytotoxicity against human HepG2.2.15 cells assessed as reduction in cell viability incubated for 3 days followed by replacement of fresh medium containing compound and measured after 3 days by cell titer glo-based luminescence assay	[PMID: 31227344]
HepG2 2.2.15	CC₅₀	15.3 μM Compound: 1	Cytotoxicity against human HepG2.2.15 cells assessed as reduction in cell viability Cytotoxicity against human HepG2.2.15 cells assessed as reduction in cell viability	[PMID: 33610748]
HepG2 2.2.15	CC₅₀	4.81 μM Compound: NVR3-778	Cytotoxicity against human HepG2.2.15 cells Cytotoxicity against human HepG2.2.15 cells	[PMID: 32173194]
HepG2 2.2.15	CC₅₀	8.6 μM Compound: NVR 3-778	Cytotoxicity against human HepG2 2.2.15 cells assessed as reduction in cell viability incubated for 5 days by MTT assay Cytotoxicity against human HepG2 2.2.15 cells assessed as reduction in cell viability incubated for 5 days by MTT assay	[PMID: 33603970]
HepG2 2.2.15	IC₅₀	0.26 μM Compound: NVR3-778	Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells by solid phase radioimmunoassay Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells by solid phase radioimmunoassay	[PMID: 32173194]

In Vitro

NVR 3-778 targets HBV core protein and inhibits viral replication^[1].
NVR 3-778 inhibits the generation of infectious HBV DNA-containing virus particles with a mean antiviral with an EC₅₀ of 0.40?μM in HepG2.2.15 cells^[1].
NVR 3-778 exhibits pan-genotypic antiviral activity and a lack of cross-resistance with nucleos(t)ide inhibitors of HBV replication^[1].
NVR 3-778 inhibits pregenomic RNA encapsidation, viral replication, and the production of HBV DNA- and HBV RNA-containing particles^[1].
NVR 3-778 also inhibits de novo infection and viral replication in primary human hepatocytes with EC₅₀s of 0.81?μM against HBV DNA and between 3.7μM and 4.8?μM against the production of HBV antigens and intracellular HBV RNA^[1].
The EC₅₀ values of NVR 3-778 are increased by 4.5-, 9.3-, and 15.8-fold in the presence of 10%, 20%, and 40% human serum, respectively^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

NVR 3-778 (1.5?mg/kg; i.g.) displays the mean C_max and AUC_0–inf values of 0.56?μg/ml and 3.50?μg·h/ml, respectively, in dogs following oral administration. And the mean oral bioavailability is determined to be 84.6%^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Dogs^[1]
Dosage:

1.5 mg/kg (Pharmacokinetic Analysis)
Administration:

Oral gavage
Result:

The mean C_max and AUC_0–inf values are 0.56 µg/ml and 3.50 µg·h/ml and the oral bioavailability is 84.6%.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 1445790-55-5
Appearance Solid
Molecular Weight 432.39
Formel C₁₈H₁₆F₄N₂O₄S
Color White to off-white
SMILES

O=C(NC1=CC(F)=C(F)C(F)=C1)C2=CC=C(F)C(S(=O)(N3CCC(O)CC3)=O)=C2
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (3)

All

Sort by:

Journal Impact Factor

Sci Rep

Identification of low-molecular compounds that inhibit envelope formation of hepatitis B virus. [Abstract]

2025 Jul 8;15(1):24344. PMID: 40624334
Microbiol Spectr

A visible assay for evaluating the inhibitory activity of drug and antibody against HBV infection. [Abstract]

2026 Apr 7;14(4):e0263825. PMID: 41810956
Anal Methods

An automated microfluidic platform for the screening and characterization of novel hepatitis B virus capsid assembly modulators. [Abstract]

2022 Jan 6;14(2):135-146. PMID: 34918017

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 250 mg/mL (578.18 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.3127 mL

11.5636 mL

23.1273 mL

5 mM

0.4625 mL

2.3127 mL

4.6255 mL

10 mM

0.2313 mL

1.1564 mL

2.3127 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (4.81 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 2.08 mg/mL (4.81 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (4.81 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (274 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Lam AM, et al. Preclinical Characterization of NVR 3-778, a First-in-Class Capsid Assembly Modulator against Hepatitis B Virus. Antimicrob Agents Chemother. 2018 Dec 21;63(1). [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.3127 mL	11.5636 mL	23.1273 mL	57.8182 mL
	5 mM	0.4625 mL	2.3127 mL	4.6255 mL	11.5636 mL
	10 mM	0.2313 mL	1.1564 mL	2.3127 mL	5.7818 mL
	15 mM	0.1542 mL	0.7709 mL	1.5418 mL	3.8545 mL
	20 mM	0.1156 mL	0.5782 mL	1.1564 mL	2.8909 mL
	25 mM	0.0925 mL	0.4625 mL	0.9251 mL	2.3127 mL
	30 mM	0.0771 mL	0.3855 mL	0.7709 mL	1.9273 mL
	40 mM	0.0578 mL	0.2891 mL	0.5782 mL	1.4455 mL
	50 mM	0.0463 mL	0.2313 mL	0.4625 mL	1.1564 mL
	60 mM	0.0385 mL	0.1927 mL	0.3855 mL	0.9636 mL
	80 mM	0.0289 mL	0.1445 mL	0.2891 mL	0.7227 mL
	100 mM	0.0231 mL	0.1156 mL	0.2313 mL	0.5782 mL

Bioz

Keywords

NVR 3-778

3 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

NVR 3-778

Publications Citing Use of MedChemExpress (MCE) NVR 3-778